Neon Names Mardene Miller Managing Director

FCB Health Network president and CEO Dana Maiman announced that Mardene Miller joined the award-winning network as co-managing director of the full-service HCP, DTP and DTC agency Neon.
FCB Health Network president and CEO Dana Maiman announced that Mardene Miller joined the award-winning network as co-managing director of the full-service HCP, DTP and DTC agency Neon.
February 01, 2019 10:17 AM Eastern Standard Time HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics. As part of the Dr. Reddy’s […]
FCB Health Network president and CEO Dana Maiman announced that Chris Seda joined the award-winning network as senior vice president and director of product design.
Vertex Pharmaceuticals Inc. terminated the employment of the company’s chief operating officer and interim chief financial officer, Ian Smith, citing “personal behavior” that violated its code of conduct.
Shares of Editas Medicine were down nearly 20 percent after CEO Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1, 2019.
GlaxoSmithKline Chairman Sir Philip Hampton will step down from his role ahead of the company’s plan to split into two separate business units.
Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, SQZ Biotech is expanding the company’s footprint in Watertown, Mass.
Fingerpaint, a full-service marketing agency with offices in Arizona, Pennsylvania, New York, Ohio and New Jersey, added Megan Davis to its account service team in Saratoga Springs, N.Y.
Fingerpaint added industry superstar Colleen Carter to lead the health and wellness agency’s marketing and business development efforts.
UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.